According to the recent research report titled ‘GLOBAL Alzheimer’s Disease Therapeutics And Diagnostic Market 2019-2027’, available with Market Study Report, global Alzheimer’s disease therapeutics and diagnostic market size is projected to expand at 7.78% CAGR over 2019-2027.
 

The report states that increasing government investments in research, booming elderly population, and growing cases of Alzheimer’s disease are key factors fostering global Alzheimer’s disease therapeutics and diagnostic market growth.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2515930/
 

Increasing investment in research & development of personalized medicines, and emerging in-vitro diagnostic techniques are also adding significant traction to the industry growth.
 

Coming to the restraints, high cost of the treatment, alongside strict government norms are hampering worldwide Alzheimer’s disease therapeutics and diagnostic industry remuneration. Moreover, lack of skilled professionals, and limited awareness regarding new therapies for Alzheimer’s treatment are negatively impacting the industry development.
 

Elaborating on therapeutics & diagnostics gamut, the market is divided into therapeutics (therapeutics by drugs, therapeutics by disease stage, prodromal stage, and therapeutics by generic & branded) and diagnostic type (computed tomography, magnetic resonance imaging, electroencephalography, positron emission tomography, lumbar puncture test, and others).
 

Citing the regional landscape, top contributors to global Alzheimer’s disease therapeutics and diagnostic market valuation are North America (Canada, United States), Europe (Russia, Italy, Spain, France, Germany, United Kingdom), Asia Pacific (South Korea, India, Japan, China), Latin America (Mexico, Brazil), and Middle East & Africa (South Africa, Saudi Arabia, Turkey, United Arab Emirates.)
 

Regionally, Asia Pacific holds considerable portion of global Alzheimer’s disease therapeutics and diagnostic industry share currently, owing to increasing government investment in research & development for drugs & diagnostic test, coupled with booming population.
 

The primary driver of the Alzheimer's disease therapeutics and diagnostic industry in China is the country's rapidly growing elderly population. As a result of the aging population's vulnerability, dementia is becoming more prevalent across the country, especially in semi-urban and rural areas.
 

Major players impacting global Alzheimer’s disease therapeutics and diagnostic market trends are Biogen Inc., Cognoptix Inc., GE Healthcare, Siemens Healthineers AG, AXON Neuroscience SE, DiaGenic ASA, Sun Pharmaceutical Industries Ltd., Amarantus BioScience Holdings Inc., Merck KGaA, Piramal Enterprises Ltd., Johnson & Johnson, Roche Holding AG, AbbVie Inc., and Baxter International.